SI3518932T1 - Zdravljenje raka prostate - Google Patents
Zdravljenje raka prostateInfo
- Publication number
- SI3518932T1 SI3518932T1 SI201731574T SI201731574T SI3518932T1 SI 3518932 T1 SI3518932 T1 SI 3518932T1 SI 201731574 T SI201731574 T SI 201731574T SI 201731574 T SI201731574 T SI 201731574T SI 3518932 T1 SI3518932 T1 SI 3518932T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| EP17823017.3A EP3518932B1 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
| PCT/EP2017/074849 WO2018060463A2 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3518932T1 true SI3518932T1 (sl) | 2025-03-31 |
Family
ID=60915459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731574T SI3518932T1 (sl) | 2016-09-30 | 2017-09-29 | Zdravljenje raka prostate |
Country Status (21)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3415517T (lt) | 2012-09-28 | 2022-06-10 | Takeda Pharmaceutical Company Limited | Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma |
| FI3518932T3 (fi) | 2016-09-30 | 2025-02-03 | Sumitomo Pharma Switzerland Gmbh | Eturauhassyövän hoito |
| DK3518933T4 (da) | 2016-09-30 | 2025-04-22 | Takeda Pharmaceuticals Co | Fremgangsmåder til behandling af uterusfibromer og endometriose |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| CN115175912B (zh) * | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| CN115279769A (zh) * | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| US20230384316A1 (en) * | 2020-10-20 | 2023-11-30 | Baylor College Of Medicine | Multiplex metabolic markers in plasma for early detection of african american prostate cancer |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| JP2024540922A (ja) | 2021-10-18 | 2024-11-06 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
| WO2023152611A1 (en) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6297379B1 (en) | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| CN1539836A (zh) | 2000-02-29 | 2004-10-27 | 武田药品工业株式会社 | 制备噻吩并嘧啶衍生物的方法 |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| EP1479684A4 (en) | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME |
| EP1480679B1 (en) | 2002-02-26 | 2007-05-23 | Astrazeneca AB | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| ATE407679T1 (de) | 2003-07-07 | 2008-09-15 | Neurocrine Biosciences Inc | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten |
| JPWO2007011072A1 (ja) | 2005-07-22 | 2009-02-05 | 武田薬品工業株式会社 | 早発排卵の防止剤 |
| KR101506750B1 (ko) | 2007-04-06 | 2015-03-27 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-방출 호르몬 수용체 길항제 및 그와 관련된 방법 |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| LT3415517T (lt) | 2012-09-28 | 2022-06-10 | Takeda Pharmaceutical Company Limited | Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| RS64377B1 (sr) | 2015-02-26 | 2023-08-31 | Takeda Pharmaceuticals Co | Tableta koja sadrži derivat metoksiuree i čestice manitola |
| WO2017040841A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| DK3518933T4 (da) | 2016-09-30 | 2025-04-22 | Takeda Pharmaceuticals Co | Fremgangsmåder til behandling af uterusfibromer og endometriose |
| FI3518932T3 (fi) | 2016-09-30 | 2025-02-03 | Sumitomo Pharma Switzerland Gmbh | Eturauhassyövän hoito |
-
2017
- 2017-09-29 FI FIEP17823017.3T patent/FI3518932T3/fi active
- 2017-09-29 EP EP24212224.0A patent/EP4520398A3/en active Pending
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 EP EP17823017.3A patent/EP3518932B1/en active Active
- 2017-09-29 ES ES17823017T patent/ES3002857T3/es active Active
- 2017-09-29 HU HUE17823017A patent/HUE070578T2/hu unknown
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/en not_active Ceased
- 2017-09-29 PL PL17823017.3T patent/PL3518932T3/pl unknown
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt not_active Application Discontinuation
- 2017-09-29 LT LTEPPCT/EP2017/074849T patent/LT3518932T/lt unknown
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 HR HRP20241740TT patent/HRP20241740T1/hr unknown
- 2017-09-29 PT PT178230173T patent/PT3518932T/pt unknown
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 CA CA3038875A patent/CA3038875A1/en active Pending
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 DK DK17823017.3T patent/DK3518932T3/da active
- 2017-09-29 SI SI201731574T patent/SI3518932T1/sl unknown
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US12097198B2/en active Active
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047B2/en active Active
-
2024
- 2024-06-28 US US18/758,904 patent/US12144809B1/en active Active
- 2024-11-05 US US18/937,891 patent/US12336990B2/en active Active
- 2024-11-25 US US18/959,460 patent/US20250082632A1/en active Pending
-
2025
- 2025-07-09 US US19/264,673 patent/US20250332166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| IL266847A (en) | Cancer treatment methods involving tigit-binding agents | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL261959B1 (en) | Cancer treatment with tg02 | |
| IL265697A (en) | Prostate cancer treatment | |
| LT3622953T (lt) | Kombinuotas vėžio gydymas | |
| PT3490560T (pt) | Niraparib para utilização num método de tratamento de cancro da próstata | |
| IL262342A (en) | Cancer treatment methods | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| GB201408297D0 (en) | Treatment of cancer | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL274748A (en) | Improved cancer treatment | |
| IL269123A (en) | Methods of treating cancer | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201711769D0 (en) | Methods of cancer therapy |